Compare Incyte Corporation (INCY) vs Valero Energy Corporation (VLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Valero Energy Corporation — how do they compare? Incyte Corporation trades at $120.58 (market cap $24.54B), while Valero Energy Corporation trades at $329.48 (market cap $93.27B). The key difference: Valero Energy Corporation is far larger — about 3.8× Incyte Corporation's market cap, and Valero Energy Corporation pays a 1.48% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | VLO | |
|---|---|---|
Market Cap | $24.54B | $93.27B |
Sector | Health | Energy |
52-Week High | $129.93 | $323.92 |
52-Week Low | $81.61 | $133.38 |
Enterprise Value | $20.04B | $96.74B |
Dividend Yield | — | 1.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.93, down 0.51% on the day, near its 52-week high. The stock shows strong fundamental momentum with Q2 2026 EPS beating estimates at $3.09 versus $2.15 expected, driven by robust Jakafi and Opzelura sales. Revenue growth accelerated to $5.14 billion in 2025, with net income margin expanding to 27.71%. Technical indicators signal a bullish trend with moving averages supporting upside, while oscillators remain neutral.
Outlook remains positive given raised 2026 revenue guidance and recent EU approval for Opzelura, though risks include competitive pressures and reliance on key products. Analyst consensus is bullish with a $122.82 price target, implying modest upside from current levels amid solid institutional ownership trends.
Valero Energy (VLO) trades at $328.43, up 4.28% today, showing strong momentum after recent earnings beats. The stock maintains bullish technical signals with key resistance at $329 and support at $319. Recent Q2 2026 results significantly exceeded expectations with EPS of $12.54 versus $10.11 estimates, driven by robust refining margins and renewable diesel performance. Revenue trends show recovery from 2025's $122.7B to projected $139.4B in 2026.
VLO presents a compelling value opportunity with attractive valuation metrics (P/E 13.51, P/S 0.7) and strong profitability (ROE 29.31%). Analyst consensus favors Buy ratings (55.55%) with $324.27 price target. Key risks include refining margin volatility and geopolitical impacts on oil markets. The company's disciplined capital allocation and dividend payments ($1.20 quarterly) provide shareholder returns amid energy sector transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Valero Energy Corporation
Valero Energy is one of the largest independent refiners in the United States. It operates 14 refineries with a total throughput capacity of 3.2 million barrels a day in the United States, Canada, and the United Kingdom. Valero also owns 14 ethanol plants with capacity of 1.7 billion gallons of ethanol a year and holds a 50% stake in Diamond Green Diesel, which has capacity to produce 700 million gallons per year of renewable diesel.
Read more on VLO →
